SAN DIEGO, CA--(Marketwire - April 1, 2011) - Quidel Corporation (
The Analyst Day presentations will begin at 8:30 a.m. Eastern Time and will conclude at 3:30 pm Eastern Time. During the presentation, the Company will discuss business and financial developments and trends. The Company's statements may contain or constitute material information that has not been previously disclosed. For further details about the event, please contact Ruben Argueta at rargueta@quidel.com.
Slides of the presentation will be available via the Investor Relations section of the Quidel website (www.quidel.com) beginning April 12th for 14 days.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well being of people around the globe through the development of rapid diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the leading brand names QuickVue®, D3® Direct Detection and Thyretain™, Quidel's products aid in the detection and diagnosis of many critical diseases and conditions, including influenza, respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid disease and fecal occult blood. Quidel's research and development engine is also developing a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests to further improve the quality of healthcare in physicians' offices and hospital and reference laboratories. For more information about Quidel's comprehensive product portfolio, visit www.quidel.com and Diagnostic Hybrids at www.dhiusa.com.
Contact Information:
Quidel Contact:
Quidel Corporation
John M. Radak
Chief Financial Officer
(858) 646-8032
Media and Investors Contact:
Quidel Corporation
Ruben Argueta
(858) 646-8023